SKP.L Regulatory News (SKP)

2 Dec 2005 10:13

Credit Suisse First Boston (Europe)02 December 2005 FORM 38.5 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS (Rule 38.5 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION Name of exempt principal trader Credit Suisse First Boston (Europe) Ltd Company dealt in Skyepharma Plc Class of relevant security to which the dealings Ordinary Sharesbeing disclosed relate (Note 1) Date of dealing 01 December 2005 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities Highest price paid (Note Lowest price paid (Note 3)purchased 3) (GBP) (GBP) 259,257 0.5325 0.51 Total number of securities Highest price received Lowest price received (Notesold (Note 3) (GBP) 3) (GBP) 224,000 0.5325 0.51 (b) Derivatives transactions (other than options) Product name, e.g. Long/short Number of securities Price per unit (Note 3)CFD (Note 4) (Note 5) (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, e.g. Expiry Optionname,e.g. selling, securities price American, date money paid/call purchasing, to which European receivedoption varying etc. the option etc. per unit relates (Note 3) (Note 5) (ii) Exercising Product name, e.g. Number of Exercise price percall option securities unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. ..................................................................... None ..................................................................... Date of disclosure 02 December 2005Contact name Dirk YoungTelephone number 020 7883 4332Name of offeree/offeror with which connected Skyepharma PlcNature of connection (Note 6) Connected Party Notes The Notes on Form 38.5 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange